Holen Sie sich die Stockscreener-App
40.97
0.00%
0.00
Handel nachbörslich:
40.99
0.02
+0.05%
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions - Minichart
Top 3 Health Care Stocks That May Collapse This Month - Benzinga
Apellis Updates Executive Separation Plan Amid Biogen Merger - TipRanks
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
MSN Money - MSN
Apellis Cell And Gene Update Puts Growth Story In Investor Focus - Sahm
Pictet Asset Management Holding SA Has $9.84 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
UBS Group AG Boosts Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases 49,642 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Jennison Associates LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis (NASDAQ: APLS) CMO reports bona fide gift of 900 shares - Stock Titan
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
M&T Bank Corp Has $1.38 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS stock soars 140% today – here’s everything to know about its massive $5.6B deal with Biogen - MSN
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Apellis earnings up next: Last report before Biogen takeover? By Investing.com - Investing.com Canada
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Apellis (APLS) Acquisition to Enhance Biogen's Growth Potential - GuruFocus
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Wednesday - MarketBeat
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Apellis Pharmaceuticals stock hits 52-week high at $40.96 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals stock hits 52-week high at $40.96 - Investing.com
Apellis surges on $5.6B buyout deal with Biogen - MSN
Apellis (NASDAQ: APLS) outlines 2025 executive pay, board and risk oversight - Stock Titan
Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on - MSN
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity - ChartMill
Why is Apellis Pharmaceuticals (APLS) down 17.3% since last earnings report? - MSN
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
Cantor Fitzgerald downgrades Apellis Pharmaceuticals (APLS) - MSN
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):